Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
AIDS Clinical Trials
100%
Antiretroviral Naïve
16%
Antiretroviral Therapy
100%
Antiretroviral Therapy Regimens
16%
Change from Baseline
16%
Complications of Therapy
16%
Dual-energy X-ray Absorptiometry
33%
Efavirenz
33%
Fasting Triglycerides
16%
Group Studies
100%
Haplogroup
50%
HIV Patients
16%
Infected Population
16%
Lamivudine
16%
Lipids
16%
Lopinavir
33%
Metabolic Changes
100%
Metabolic Disease
16%
Metabolic Parameters
16%
Mitochondrial DNA
16%
Mitochondrial Haplogroups
100%
Non-high-density Lipoprotein Cholesterol (non-HDL-C)
33%
Non-Hispanic White
16%
Nucleoside Reverse Transcriptase Inhibitors
100%
Self-identification
16%
Tenofovir
33%
Three-class
16%
White People
16%
Whole-body
16%
Zidovudine
33%
Medicine and Dentistry
Antiretroviral Therapy
100%
Clinical Trial
100%
Dual-Energy X-Ray Absorptiometry
33%
Efavirenz
33%
Haplogroup
50%
High Density Lipoprotein Cholesterol
33%
Human Immunodeficiency Virus
16%
Lamivudine
16%
Lopinavir/Ritonavir
33%
Mitochondrial DNA
16%
Mitochondrial Haplogroup
100%
Reverse-Transcriptase Inhibitor
100%
Tenofovir
33%
Water-Electrolyte Imbalance
16%
Zidovudine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Efavirenz
33%
High Density Lipoprotein Cholesterol
33%
HIV
16%
Lamivudine
16%
Lopinavir Plus Ritonavir
33%
Metabolic Disorder
16%
Mitochondrial DNA
100%
RNA Directed DNA Polymerase Inhibitor
100%
Zidovudine
33%
Neuroscience
Dual-Energy X-Ray Absorptiometry
25%
Efavirenz
25%
Haplogroup
100%
High Density Lipoprotein Cholesterol
25%
Human Immunodeficiency Virus
12%
Lamivudine
12%
Mitochondrial DNA
100%
Reverse-Transcriptase Inhibitor
75%
Zidovudine
25%